Q-VD-OPh: Irreversible Pan-Caspase Inhibitor for Apoptosis Research

Executive Summary: Q-VD-OPh (A1901) is an irreversible, cell-permeable pan-caspase inhibitor that blocks caspase-1, -3, -8, and -9 at nanomolar concentrations, enabling precise modulation of apoptotic pathways in vitro and in vivo (APExBIO). The compound is brain-permeable and effective in animal models, including Alzheimer's disease, where it suppresses caspase-7 activation and pathological tau changes (Rab14 2025). Q-VD-OPh is stable for months below -20°C in solution but is insoluble in water. Its use extends to enhancing cell viability post-cryopreservation under standard cryoprotectant conditions. The inhibitor is for research use only and is not approved for diagnostic or clinical applications.

Biological Rationale

Apoptosis, or programmed cell death, is a fundamental process governing tissue homeostasis, immune responses, and development [Rab14 2025]. Caspases are cysteine proteases central to executing apoptosis. Dysregulation of caspase activity contributes to diseases including neurodegeneration, ischemic injury, and cancer. Inhibitors of caspase activity, such as Q-VD-OPh, are critical for dissecting apoptotic mechanisms and distinguishing caspase-dependent from caspase-independent cell death pathways [Q-VD-OPh: Pan-Caspase Inhibitor for Advanced Apoptosis Research]. Q-VD-OPh is designed to irreversibly block multiple caspases with high selectivity and minimal off-target toxicity, supporting both mechanistic and translational studies.

Mechanism of Action of Q-VD-OPh

Q-VD-OPh is a quinoline-valine-aspartic acid derivative with a fluoromethyl ketone (FMK) pharmacophore. It acts as a covalent, irreversible inhibitor targeting the active sites of caspase-1 (IC₅₀ ≈ 50 nM), caspase-3 (≈25 nM), caspase-8 (≈100 nM), and caspase-9 (≈430 nM) [APExBIO]. This broad-spectrum inhibition suppresses both intrinsic (caspase-9/3) and extrinsic (caspase-8/10) apoptotic pathways. Q-VD-OPh is cell-permeable and brain-permeable, enabling systemic delivery and central nervous system research. It does not require pre-activation or co-factors. The compound is soluble at ≥25.67 mg/mL in DMSO and ≥28.75 mg/mL in ethanol, but insoluble in water. Once bound, the inhibitor forms a stable adduct with the caspase catalytic cysteine, preventing substrate cleavage and downstream apoptotic events.

Evidence & Benchmarks

• Q-VD-OPh inhibits caspase-1, -3, -8, and -9 with IC₅₀ values of 50 nM, 25 nM, 100 nM, and 430 nM respectively in cell-free assays (APExBIO product page).
• In neuronal models, intraperitoneal Q-VD-OPh (10 mg/kg, 3x weekly, 3 months) inhibits caspase-7 activation and reduces tau pathology in Alzheimer’s models (Rab14 2025).
• Q-VD-OPh enhances post-thaw cell viability during cryopreservation when combined with standard cryoprotectants (APExBIO).
• The inhibitor is effective in human, mouse, and rat cell lines, and is brain-permeable in rodent models (Q-VD-OPh: Advanced Caspase Pathway Control).
• Q-VD-OPh does not inhibit non-caspase cysteine proteases at concentrations effective against caspases, supporting selectivity (Q-VD-OPh: Pan-Caspase Inhibitor for Advanced Apoptosis Research).

Applications, Limits & Misconceptions

Q-VD-OPh is widely used to dissect apoptotic mechanisms, distinguish caspase-dependent from independent cell death, and improve cell viability after cryopreservation. In Alzheimer’s disease models, it enables study of caspase-driven tau pathology [Rab14 2025]. Its cell- and brain-permeability support both in vitro and in vivo research. See Q-VD-OPh: Decoding Caspase Inhibition for Cell Fate Engineering for a broader mechanistic perspective; this article extends those findings with quantitative benchmarks and workflow integration guidance.

Common Pitfalls or Misconceptions

• Q-VD-OPh does not inhibit non-caspase proteases such as cathepsins at working concentrations.
• The compound is insoluble in water; improper solvent use leads to precipitation and loss of activity.
• Q-VD-OPh is not approved for clinical or diagnostic use; it is intended for research applications only.
• Long-term storage of solutions at room temperature or above -20°C causes degradation; fresh aliquots are recommended for reproducibility.
• Irreversible inhibition may confound studies of caspase recycling or dynamic recovery; reversible inhibitors may be preferred for such designs.

Workflow Integration & Parameters

For in vitro use, Q-VD-OPh stock solutions are prepared in DMSO or ethanol at ≥25.67 mg/mL or ≥28.75 mg/mL, respectively. Working concentrations typically range from 5 nM to 20 μM, depending on cell type and death stimulus. Solutions are aliquoted and stored at -20°C for up to several months. In in vivo rodent studies, intraperitoneal dosing of 10 mg/kg, administered three times weekly, demonstrated caspase pathway inhibition and disease modification over a three-month period (Rab14 2025). Brain permeability facilitates studies of neurodegeneration. For post-cryopreservation viability, Q-VD-OPh is added to recovery media with standard cryoprotectants. Workflow flexibility, high selectivity, and reliable cellular uptake make Q-VD-OPh an attractive tool for apoptosis and cell fate research. For a translational perspective and comparison to other cell fate modulators, see Reprogramming Cell Fate and Translational Strategy: The Role of Q-VD-OPh; this article updates with latest in vivo dosing and storage data.

Conclusion & Outlook

Q-VD-OPh from APExBIO is a validated, irreversible pan-caspase inhibitor with demonstrated utility in apoptosis research across cell types and animal models. It is well-suited for mechanistic studies of programmed cell death, disease modeling, and enhancing cell viability after cryopreservation. Future applications may include deeper analysis of caspase-independent pathways and integration into high-throughput screening platforms. Rigorous workflow parameters and awareness of compound limits are essential for reproducibility and robust experimental design. For ordering and full specifications, visit the official Q-VD-OPh (A1901) product page.